$5.53
+11%OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients. The company's products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages. It also offers brand support services, which focuses on educating and working with pharmaceutical manufacturers on identifying, formulating, and implementing eRx media strategies, including drug file integration, sales force training, and strategy development services for promoting their products. In addition, the company operates cloud based Mobile Health Messenger platform that provides interactive health messaging for enhanced medication adherence and care coordination; and HIPAA-compliant automated mobile messaging platform, which allows pharmaceutical manufactures and related entities to directly engage with patients to enhance regimen compliance. Further, it offers patient programs with treatment and affordability information, lifestyle and condition trackers, internet device connectivity, forms, and surveys. Additionally, the company provides evidence-based physician engagement solution applied to real-world data to assist healthcare providers in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations. It also offers therapy initiation workflow focused on accelerating patient access to treatments where time-consuming medical documentation is required of HCPs prior to pharmacies dispensing prescribed drugs. The company was found in 2006 and is headquartered in Rochester, Michigan.
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Exceptional cash generation: High-quality earnings converting to growing free cash flow. The company demonstrates strong pricing power, efficient operations, and disciplined capital allocation.
OPRX โข NASDAQ
| OptimizeRx Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||||||||||||||
5.1M | -20.1M | -17.6M | -11.4M | 378.1K | -2.2M | -3.1M | 226.3K | -2.1M | -1.5M | -595.1K | -1M | 215.8K | -364K | -2.1M | -2M | -4.6M | -4.2M | -361.5K | |
4.3M | 4.3M | 2.4M | 2M | 2M | 2.1M | 1.3M | 316.5K | 324.6K | 235.3K | 334K | 264.3K | 193.8K | 187.1K | 145.3K | 59.9K | 32.5K | 32.2K | 2.8K | |
1.2M | 1.4M | 0.0 | 0.0 | 0.0 | 200K | -898K | 2.4K | 65.7K | 0.0 | 31.7K | 3.3K | 0.0 | 6.9K | 916.7K | 142.4K | 0.0 | 0.0 | 0.0 | |
7M | 11.5M | 13.7M | 15.7M | 5.5M | 3.2M | 2.3M | 1.9M | 87.4K | 175.2K | 327.7K | 899.4K | 399.1K | 180.6K | 189.5K | 473.8K | 0.0 | 333K | 0.0 | |
264K | 6.8M | 9.8M | 363.5K | 80K | 140.4K | 635K | 656.9K | 815K | 384.1K | 253.4K | 272.8K | 19.5K | 89.6K | 184.1K | 8K | 2.9M | 2.8M | 0.0 | |
(0.0) | (161K) | (48K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
816K | 921K | -15.6M | 4M | -7.2M | -9.7M | -1.8M | -2.3M | -668.5K | 278.7K | 163.5K | -470.8K | 304.4K | -724.3K | 163.6K | 13.5K | -193.9K | 149K | 55K | |
18.7M | 4.9M | -7.2M | 10.7M | 726K | -6.3M | -1.7M | 792.6K | -1.5M | -466K | 515.1K | -56.4K | 1.1M | -624K | -521.5K | -1.3M | -1.8M | -919.4K | -303.6K | |
INVESTING ACTIVITIES | |||||||||||||||||||
-58K | -112K | -87K | -81K | -100.3K | -68K | -1.6M | -91K | -42.2K | -349.5K | -101K | -410K | -298.6K | -50.9K | -234.9K | -225.6K | -107.7K | -10.6K | -125.6K | |
(0.0) | (0.0) | -80.4M | -2M | (0.0) | (0.0) | -9M | -5.6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
(0.0) | (0.0) | -162.8M | -55.9M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
0.0 | 0.0 | 218.7M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
126K | -338K | -774K | -163.6K | -385.7K | -56.7K | 0.0 | -56.7K | 0.0 | -171.1K | -98.9K | -403K | -298.6K | -48.6K | -5K | 0.0 | -1.1M | 0.0 | 0.0 | |
(68K) | -450K | -25.3M | -58.2M | -486K | -124.7K | -10.6M | -5.7M | -42.2K | -349.5K | -101K | -410K | -298.6K | -50.9K | -239.9K | -225.6K | -107.7K | -10.6K | -125.6K | |
FINANCING ACTIVITIES | |||||||||||||||||||
352K | -911K | -7.5M | -20M | 70.7M | 2.5M | 21.3M | 8.2M | -390K | -357.4K | 4.3M | 2.8M | 0.0 | 0.0 | 0.0 | 8.8K | 35K | 636K | 300K | |
-8M | -4M | 36M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1M | 1M | -4K | -323.8K | 70K | |
(0.0) | -911K | -7.5M | -20M | (0.0) | (0.0) | (0.0) | (0.0) | -390K | -806.9K | (0.0) | -6M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-1.2M | 0.0 | -278K | 1.1M | 3.3M | -4.4M | 877.7K | 521.3K | 0.0 | 0.0 | 0.0 | 0.0 | -233.9K | 0.0 | 1.1M | 0.0 | 0.0 | 0.0 | 180K | |
-8.8M | -4.9M | 28.2M | -19M | 73.9M | -1.9M | 22.2M | 8.7M | -390K | -357.4K | 4.3M | 2.8M | 233.9K | 0.0 | 442.5K | 2.2M | 31K | 3.3M | 550K | |
CASH FLOW SUMMARY | |||||||||||||||||||
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -233.9K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
10M | -472K | -4.4M | -66.5M | 74.2M | -8.3M | 9.9M | 3.8M | -1.9M | -1.2M | 4.8M | 2.3M | 834K | -674.9K | -318.9K | 621.7K | -1.8M | 2.4M | 120.8K | |
13.4M | 13.9M | 18.2M | 84.7M | 10.5M | 18.9M | 8.9M | 5.1M | 7M | 8.2M | 3.4M | 1.1M | 284.3K | 959.2K | 1.3M | 656.4K | 2.5M | 135.4K | 14.6K | |
23.4M | 13.4M | 13.9M | 18.2M | 84.7M | 10.5M | 18.9M | 8.9M | 5.1M | 7M | 8.2M | 3.4M | 1.1M | 284.3K | 959.2K | 1.3M | 656.4K | 2.5M | 135.4K | |
18.7M | 4.8M | -8.1M | 10.4M | 240K | -6.4M | -3.2M | 701.5K | -1.5M | -815.5K | 414.1K | -466.3K | 834K | -674.9K | -756.4K | -1.5M | -1.9M | -930K | -429.2K |
OPRX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 30, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 09, 2026 | April 03, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 24, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 12, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 07, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 06, 2025 | November 06, 2025 | 2025 | |
8-K 8-K 2025 N/A | August 19, 2025 | August 15, 2025 | 2025 |
Continue your OPRX research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.